Everolimus is under clinical development by Novartis and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute ...
Market value in U.S. dollars: $203.0 billion Novartis, a giant of pharmaceutical industry, is based in Basel, Switzerland though it serves customers all over the world. Novartis’s subsidiaries ...
The US FDA has approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast ...